South Korea Antiviral Market Insight
Published: 05 June 2026 | Report Format: Electronic (PDF)
The South Korean antiviral market is expected to experience an increase at a rate of 7.33% owing to rising prevalence of viral infections, increasing healthcare expenditure, growing demand for antiviral therapeutics, and advancements in pharmaceutical research.
South Korea Antiviral Market Insights Forecasts to 2035
- The South Korea Antiviral Market Size Was Estimated USD 1.42 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 7.33% from 2025 to 2035
- The South Korea Antiviral Market Size is Expected to rise around USD 2.88 Million by 2035
Notable Insights for the South Korea Antiviral Market
- The product-based segmentation indicates that the Direct-Acting Antivirals (DAAs) segment holds a commanding position with almost 55% market share South Korea Antiviral Market 2025 due to its growing usage in hepatitis, influenza.
- The application-based segmentation shows that the Hepatitis, I segment dominates with a market share of almost 61% South Korea Antiviral Market in 2025 result of increasing prevalence of viral diseases improved access to antiviral therapies.
- The global revenue for Gilead Sciences, Inc. in fiscal year 2025 was estimated at about $28.6 billion, driven by rising demand for antiviral medicines, infectious disease treatments, and specialty pharmaceutical products.
- As per expectations, increasing investments in antiviral drug development and advanced treatment approaches along with rising healthcare awareness will drive market expansion in which antiviral therapies improve treatment effectiveness by up to 42% and reduce hospitalization risks by up to 31%.
Download the eBook (ToC)
Research Methodologies Used to Analyze the South Korea Antiviral Market
The South Korea antiviral market is analyzed by a blend of primary and secondary research approaches for ensuring accurate information about the market and its forecasted performance. Primary research is conducted through discussions with pharmaceutical manufacturers, healthcare organizations, hospitals, infectious disease specialists, distributors, and industry experts to analyze demand trends, technological progress, and competitive activities. Secondary research will involve analyzing reports published by companies and governments, healthcare journals, clinical studies, industry databases, and pharmaceutical organizations in connection with antiviral therapeutics and infectious disease management. Market estimation, trend analysis, and forecasting methods will be used for estimating market size, growth opportunities, price dynamics, and investments.
Decisions Advisors Research Methodology: Trusted Insights for Strategic Decision-Making
What is Decisions Advisors Research?
Decisions Advisors research delivers comprehensive market intelligence through detailed industry analysis, competitive benchmarking, trend forecasting, and data-driven business insights. Our research methodology combines advanced analytical frameworks with extensive primary and secondary research to help organizations make informed and strategic business decisions.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the South Korea Antiviral Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in South Korea Antiviral Market
· Gilead Sciences, Inc.
· Pfizer Inc.
· F. Hoffmann-La Roche Ltd.
· Merck & Co., Inc.
· AbbVie Inc.
· Bristol Myers Squibb Company
· Johnson & Johnson
· GlaxoSmithKline plc
· Samsung Bioepis Co., Ltd.
· Celltrion Inc.
Recent Developments:
- In January 2026, Horiba Ltd. expanded its Raman spectroscopy portfolio with AI-enabled molecular analysis systems designed for semiconductor research and pharmaceutical quality testing applications.
- In August 2025, Celltrion Inc. introduced next-generation antiviral biologic development programs designed for infectious disease treatment and enhanced pharmaceutical innovation within the South Korean healthcare market.
Market Segmentation:
South Korea Antiviral Market, By Product Type
- Direct-Acting Antivirals (DAAs)
- Nucleoside Analog Antivirals
- Protease Inhibitors
- Neuraminidase Inhibitors
- Combination Antiviral Therapies
South Korea Antiviral Market, By Technology
- Small Molecule Antiviral Drugs
- Biologic Antiviral Therapies
- Monoclonal Antibody-Based Treatments
- RNA-Based Antiviral Technologies
- Advanced Drug Delivery Systems
South Korea Antiviral Market, By Application
- Hepatitis Treatment
- Influenza Treatment
- HIV Treatment
- Respiratory Viral Infections
- Other Viral Diseases
Expert Views:
The growth of antiviral markets in South Korea will be facilitated by increased demand for effective infectious disease treatments, rising prevalence of chronic viral infections, and growing investments in pharmaceutical research. The use of advanced antiviral therapeutics, biologic drug development, and innovative treatment technologies will contribute to improved patient outcomes and enhanced demand in hepatitis treatment, influenza management, HIV therapy, and infectious disease care markets in South Korea.
Author: Govind and Krishna By Spherical Insights and Consulting